世界の眼痛市場規模、シェア、トレンド分析レポート
Market Size in USD Billion
CAGR :
% 
USD
1.12 Billion
USD
2.02 Billion
2024
2032
 予測期間 |
2025 –2032 |
 市場規模（基準年） |
USD 1.12 Billion |
 Market Size (Forecast Year) |
USD 2.02 Billion |
 CAGR |
% |
| Major Markets Players |
|
世界の眼痛市場セグメンテーション、疾患タイプ別（眼疾患を伴う眼痛と一次性眼疾患を伴わない眼痛）、タイプ別（診断と治療）、用途別（結膜炎、角膜剥離、眼瞼炎、麦粒腫、虹彩炎、副鼻腔炎、片頭痛、緑内障など）、投与経路別（局所、眼周囲、眼内、経口）、薬剤タイプ別（処方薬と市販薬）、対象者タイプ別（成人および高齢者）、エンドユーザー別（病院、専門クリニック、在宅医療施設、眼科センター、外来手術センターなど）、流通チャネル別（直接入札、病院薬局、小売薬局、オンライン薬局など） - 2032年までの業界動向と予測
眼痛市場規模
- 世界の眼痛市場規模は2024年に11億2000万米ドルと評価され、予測期間中に7.8％のCAGRで成長し、2032年には20億2000万米ドル に達すると予想されています 。
- 市場の成長は主に、不衛生で座りがちなライフスタイルの増加によって促進されている。
- さらに、眼痛は人々の眼関連疾患に対する意識を高めています。これらの要因が重なり、眼痛治療ソリューションの普及が加速し、業界の成長を大きく後押ししています。
眼痛市場分析
- 医薬品や非医薬品によるアプローチを含む眼痛治療は、外傷、感染症、炎症、手術後の回復によって引き起こされる眼の不快感を管理するのに効果的であるため、注目を集めています。
- 眼疾患の増加、スクリーンタイムの増加、人口の高齢化、眼の健康に対する意識の高まりが相まって、眼痛管理ソリューションの需要が世界中で高まっています。
- 北米は、高齢化人口の増加、眼科医療へのアクセス拡大、米国、カナダなどの主要経済圏における医療費の増加に支えられ、2025年には45.05%という最大の収益シェアで眼痛市場を支配すると予想されています。
- 北米は、ドライアイ症候群の増加、都市の大気汚染、デジタル機器の使用、大手製薬会社の存在感の高まりにより、予測期間中に眼痛市場で最も急速に成長する地域になると予想されています。
- 眼疾患に伴う眼痛治療セグメントは、炎症や術後痛を軽減する効果、入手の容易さ、臨床現場での幅広い採用により、2025年には73.17%の市場シェアを獲得し、眼痛市場を支配すると予想されています。
レポートの範囲と眼痛市場のセグメンテーション
|
属性 |
眼痛に関する主要な市場洞察 |
|
対象セグメント |
|
|
対象国 |
アジア太平洋
北米
ヨーロッパ
南アメリカ
中東およびアフリカ
|
|
主要な市場プレーヤー |
|
|
市場機会 |
|
|
付加価値データ情報セット |
データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、輸出入分析、生産能力概要、生産消費分析、価格動向分析、気候変動シナリオ、サプライチェーン分析、バリューチェーン分析、原材料/消耗品概要、ベンダー選択基準、PESTLE分析、ポーター分析、規制枠組みも含まれています。 |
眼痛市場の動向
眼性片頭痛の症例増加
- 眼痛市場における世界的な牽引力の一つは、眼性片頭痛の増加です。片頭痛は、特に若年成人において、一時的な視力低下や激しい眼痛を引き起こす神経疾患です。この負担の増大は、眼の不快感の神経的および血管的原因を標的とした、効果的で多分野にわたる治療の必要性を浮き彫りにしています。
- 例えば、API Care Onlineによると、2025年6月には、片頭痛に伴う眼痛の多因子病態生理を分析するナラティブレビューが発表され、神経、血管、感覚経路の相互作用が強調されました。この研究では、診断が遅れがちなこれらの症状に対処するために、早期診断と連携した治療アプローチの必要性が訴えられました。
- 同月、Mivisionはランダム化クロスオーバー試験の結果を発表し、片頭痛とドライアイの両方を患う患者において、眼の潤滑が片頭痛の重症度を有意に軽減したことを実証しました。これは、ドライアイの症状を管理することで片頭痛による眼痛を軽減できることを示唆しており、これらの疾患の重複性を強調しています。
- 眼性片頭痛は急性で一時的なことが多いですが、持続性となり、眼痛や視覚障害の繰り返し発作を引き起こすこともあります。こうした症例の増加は、眼痛管理ソリューションに対する世界的な需要の高まりに大きく貢献しています。
- 眼性片頭痛の症例の増加は、臨床的認識の高まりと新たな治療介入と相まって、特に神経学と眼科の統合ケアの現場において、世界的な眼痛市場の拡大を推進する極めて重要な要因となっています。
眼痛市場の動向
ドライバ
眼疾患に対する人々の意識向上
- 眼疾患とその初期症状（眼痛など）に対する意識の高まりは、世界の眼痛市場を牽引する大きな原動力となっています。特に発展途上地域では、啓発活動や公衆衛生キャンペーンを通じて、患者が適切なタイミングで診断と介入を受けるよう促されています。
- 例えば、2023年1月にMDPIに掲載されたポーランドにおける一般的な眼疾患に関する調査では、白内障や緑内障などの疾患を国民のかなりの割合が認識していることが明らかになりました。認知度はまだ向上の余地があるものの、この調査では、眼痛などの症状に対する早期治療を促進するための公衆衛生イニシアチブにおいて、こうした基礎知識を効果的に活用できることが強調されています。
- さらに、2025年3月には、LVPEIはインドのオリッサ州で緑内障啓発ウォークを開催し、約200人が参加しました。これは、世界中で8000万人以上が罹患しているこの疾患への関心を高めるためのものでした。このイベントでは、参加者に対し、初期症状としての眼痛、リスク要因、利用可能な治療法などについて啓発するインタラクティブなセッションが行われました。
- 政府のプログラム、機関の取り組み、そして地域社会の関与によって促進された意識の高まりは、眼疾患の早期発見と治療の見通しを着実に改善させています。この変化は、より多くの患者が病気の進行のより早い段階で専門的なケアを求めるようになり、世界の眼痛市場の成長に大きく貢献しています。
抑制/挑戦
高額な眼科治療と投薬
- 眼痛の治療費と薬剤費の高騰は、市場拡大の大きな障壁となっています。特に慢性疾患に対する高度な治療や処方点眼薬は、多くの患者にとって高額であり、適切な治療へのアクセスと継続を制限しています。
- 例えば、2024年11月、BMC Ophthalmologyによると、緑内障などの慢性眼疾患における患者の服薬不遵守の主な要因として、高額な薬剤費が挙げられました。ガーナの農村部で行われた研究では、費用負担やアクセスといった社会経済的障壁が治療の有効性と継続性を低下させていることが強調されました。
- さらに、眼痛治療のための高度な刺激療法は最大95％の成功率を示しているものの、その高額な費用は先進国と発展途上国の両方で平均所得の患者のほとんどにとって手の届かないものであり、広く普及することを妨げている。
- 技術の進歩と医療改革は、長期的には治療費の低減につながる可能性がありますが、眼痛治療薬の高価格は、特にコストに敏感な市場において依然として大きな制約となっています。保険適用、価格規制、ジェネリック医薬品の代替品提供などを通じて、手頃な価格での治療を実現することは、市場浸透の拡大と患者アウトカムの改善に不可欠です。
眼痛市場の展望
市場は、病気の種類、タイプ、用途、投与経路、薬物の種類、人口の種類、エンドユーザー、流通チャネルに基づいてセグメント化されています。
- 病気の種類別
疾患の種類に基づいて、眼痛市場は、眼疾患を伴う眼痛と、眼疾患を伴わない眼痛に分類されます。2025年には、緑内障、白内障、ドライアイ症候群、ぶどう膜炎といった疾患の世界的な罹患率の上昇を背景に、眼疾患を伴う眼痛セグメントが73.17%の市場シェアを獲得し、市場を牽引すると予想されます。このセグメントは、認知度の高まり、診断率の向上、ステロイド点眼薬、抗炎症薬、刺激療法といった標的療法の利用可能性の拡大といった恩恵を受けています。外科手術の増加と効果的な術後疼痛管理の必要性も、このカテゴリーの需要をさらに押し上げています。
眼疾患に伴う眼痛セグメントは、加齢に伴う眼疾患の発生率増加と世界的な高齢者人口の増加を背景に、2025年から2032年にかけて7.5%という最も高い成長率を示すと予測されています。新規眼科薬の開発と疾患の早期発見技術の進歩が、持続的な市場成長を支えています。眼痛を引き起こす眼疾患の治療に積極的に取り組む患者が増えるにつれ、このセグメントにおける専門治療への需要は高まり続けています。
- タイプ別
眼痛市場は、種類別に診断と治療の2つに分類されます。2025年には、細隙灯顕微鏡検査、眼圧測定、光干渉断層撮影（OCT）、神経学的評価といった高度な診断ツールの利用増加に支えられ、診断分野が眼痛市場において主要な市場となるでしょう。緑内障、片頭痛、感染症といった根本原因の早期かつ正確な診断は、適切な疼痛管理戦略を策定する上で不可欠です。眼科医療インフラの整備と意識の高まりは、先進国市場と発展途上国市場の両方で診断の普及を促進しています。
診断分野は、ステロイド点眼薬、NSAIDs（非ステロイド性抗炎症薬）、人工涙液、そして新たな刺激療法など、効果的な眼痛緩和ソリューションへの需要増加に牽引され、2025年から2032年にかけて最も高いCAGR（年平均成長率）が見込まれます。これらの治療選択肢は、手術後の回復、緑内障、片頭痛、炎症性眼疾患に伴う眼痛の管理において、医療従事者に広く好まれています。高度な薬剤処方と治療技術の利用可能性が高まっていることから、この分野は病院と小売の両方の環境で優位に立っています。
- アプリケーション別
眼痛市場は、用途別に、結膜炎、角膜剥離、眼瞼炎、ものもらい、虹彩炎、副鼻腔炎、片頭痛、緑内障などに分類されます。結膜炎セグメントは、2025年に大きな市場収益シェアを占めました。これは、ウイルス性結膜炎と細菌性結膜炎の両方が世界的に高い発生率を示し、炎症、充血、眼痛を引き起こすことが主な要因です。「はやり目」として知られる結膜炎は、あらゆる年齢層の人々に発症し、地域社会で容易に広がるため、鎮痛点眼薬や抗炎症薬の需要が高まっています。
緑内障分野は、世界的な緑内障罹患率の上昇と高齢化社会における緑内障リスクの高まりを背景に、2025年から2032年にかけて9.3%という力強い成長率を記録すると予測されています。早期診断の重要性に対する意識の高まりに加え、手術技術や薬剤送達システムの進歩が市場拡大を促進しています。さらに、革新的な治療法の登場と眼科医療へのアクセス向上も、緑内障管理ソリューションの需要をさらに加速させています。
- 投与経路
投与経路に基づき、眼痛治療薬市場は、局所投与、眼周囲投与、眼内投与、経口投与、その他に分類されます。局所投与セグメントは、その適用の容易さ、効果の発現の速さ、そして入手しやすさから、2025年には最大の市場収益シェアを占めました。点眼薬、ゲル剤、軟膏などの局所投与製剤は、結膜炎、角膜剥離、ドライアイ、手術後炎症などの症状によって引き起こされる眼痛の管理に一般的に処方されます。非侵襲性と局所的な緩和効果を得られることから、医療従事者と患者の両方から好まれる選択肢となっています。
局所用セグメントは、非侵襲性で簡便な治療オプションに対する患者の嗜好の高まりを背景に、2025年から2032年にかけて7.9%という最も高い成長率を記録すると予測されています。局所製剤の利点、例えば標的への薬剤送達や全身性副作用の軽減といった認識の高まりが、導入を後押ししています。さらに、点眼薬のゲル剤、点眼薬、軟膏剤における継続的なイノベーションと、眼の不快感を抱えやすい高齢者人口の増加が、このセグメントの持続的な市場成長を支えると予想されます。
- 薬剤の種類別
薬剤の種類に基づいて、眼痛治療市場は処方薬と市販薬に分類されます。2025年には、専門的な医療監督を必要とする慢性および重篤な眼疾患の増加に牽引され、処方薬セグメントが最大の市場収益シェアを占めました。コルチコステロイド、非ステロイド性抗炎症薬（NSAID）、高度な点眼薬などの処方薬による治療は、手術後の回復期、緑内障、ぶどう膜炎、その他の視力を脅かす疾患に伴う眼痛の管理に広く利用されています。医師の指導が必要であり、処方薬による治療は高い有効性を持つことから、患者と医療提供者の間で信頼できる選択肢となっています。
処方薬セグメントは、複雑な眼疾患の診断率の上昇と長期的な眼科ケアを必要とする高齢者人口の増加を背景に、2025年から2032年にかけて8.0%という最も高い成長率を達成すると予測されています。眼科医へのアクセス向上と、安全性と有効性プロファイルが向上した新規処方薬の継続的な開発が、需要を牽引しています。さらに、医療保険の適用範囲の拡大と、処方薬を選択する患者の意欲も、このセグメントの持続的な市場成長を支えると予想されます。
- 人口タイプ別
人口タイプに基づいて、眼痛市場は成人と高齢者に区分されます。2025年には、成人セグメントが最大の市場収益シェアを占めました。これは、デジタル眼精疲労、片頭痛、アレルギー、軽度の外傷などに関連する眼痛の発生率の上昇が要因です。スクリーンタイムの増加、環境汚染物質への曝露、そしてライフスタイルに起因するストレスにより、成人は眼の不快感を感じやすくなり、処方薬と市販薬の両方による鎮痛ソリューションの需要が高まっています。
成人の眼痛分野は、視力障害、デジタル眼精疲労、生活習慣病の増加に牽引され、2025年から2032年にかけて8.1%という力強い成長率を記録すると予測されています。眼の健康に対する意識の高まりと、先進的な眼科治療の導入拡大が相まって、成人における治療需要を押し上げています。さらに、標的を絞った疼痛管理ソリューションの利用可能性と専門医療へのアクセス拡大が、この分野の市場成長を加速させると予想されます。
- エンドユーザー別
エンドユーザーに基づいて、眼痛市場は病院、専門クリニック、在宅医療施設、眼痛センター、外来手術センター、その他に分類されます。病院セグメントは、眼科手術、外傷治療、そして緊急の疼痛管理を必要とする急性眼疾患の患者数の増加に牽引され、2025年には最大の市場収益シェアを占めました。病院は、眼周囲注射、処方薬、術後ケアなどの高度な治療を行う主要な拠点であり、中等度から重度の眼痛症例の管理における重要な拠点となっています。
病院セグメントは、高度な眼科医療を求める患者数の増加と眼疾患の罹患率の上昇に牽引され、2025年から2032年にかけて9.0%という最も高い成長率を記録すると予測されています。病院インフラの継続的な改善、専門眼科医の確保、最先端の診断・外科技術の導入が、市場拡大をさらに後押ししています。眼痛や関連疾患の包括的な治療を求めて病院を選択する患者が増えるにつれ、このセグメントにおける専門的な眼科医療の需要は加速し続けています。
- 流通チャネル別
流通チャネルに基づいて、眼痛市場は直接入札、病院薬局、小売薬局、オンライン薬局、その他に分類されます。2025年には、直接入札セグメントが最大の市場収益シェアを占めました。これは、政府契約や機関供給契約を通じた公立・私立病院による眼痛治療薬および治療法の大規模調達が牽引役となっています。直接入札は、特に医療システムが中央集権化されている国において、コスト効率と合理化されたサプライチェーンを確保します。このセグメントは、外科的疼痛および慢性疼痛管理に使用される重要な眼科用医薬品および機器の大量購入に好まれるチャネルです。
直接入札セグメントは、医療施設や政府機関における費用対効果の高い調達モデルへの関心の高まりを背景に、2025年から2032年にかけて8.7%という最も高い成長率を記録すると予想されています。一括購入の重要性が高まり、透明性の高い入札プロセスと相まって、価格効率が向上し、高品質な医療製品へのアクセスが確保されます。サプライチェーンの合理化と仲介コストの削減を目的として直接入札の仕組みを導入する病院や公衆衛生機関が増えるにつれ、このセグメントの需要は引き続き高まっています。
眼痛市場の地域分析
- 北米は、緑内障、ドライアイ、眼性片頭痛などの慢性眼疾患の罹患率の高さ、強力な医療インフラ、先進的治療法の早期導入により、眼痛市場で優位に立ち、2025年には総収益の45.05%を占めると予想されています。
- この地域は、強力な研究開発投資、眼科医療への広範なアクセス、早期診断と眼の健康に関する意識の高まりといった恩恵を受けており、処方薬と市販薬の両方の眼痛治療薬の継続的な成長を支える要因となっています。
- 米国やカナダなどの主要国は、臨床試験の拡大、高い保険適用範囲、強力な医薬品パイプラインにより、眼科のイノベーションの最前線に立っており、新しい眼痛管理治療法の利用を促進しています。
- 老年人口の増加、一人当たりの医療費の増加、そして大手市場プレーヤーと眼科医療団体の存在は、世界の眼痛市場における北米の影響力をさらに高めています。
米国眼痛市場に関する洞察
米国の眼痛市場は、2025年に北米の眼痛市場において最大の市場収益シェアを占めました。これは、先進的な医療インフラ、緑内障、ドライアイ症候群、眼性片頭痛といった慢性眼疾患の有病率の高さ、そして大手製薬会社の強力なプレゼンスによるものです。高齢化人口の増加、高い保険普及率、処方薬や先進的な治療法の普及は、効果的な眼痛管理に対する継続的な需要を支えています。眼科用薬物送達システムにおける継続的なイノベーションと患者の意識の高まりが、市場拡大をさらに促進しています。
カナダ眼痛市場に関する洞察
カナダの眼痛市場は、眼科医療への投資増加、加齢に伴う眼疾患の発生率上昇、そして眼痛への早期介入に対する国民の意識向上を背景に、2025年から2032年にかけて北米で大幅な年平均成長率（CAGR）を記録すると予想されています。カナダは強力な公的医療制度を有し、眼科医療へのアクセスと治療費の補助を充実させています。また、予防可能な視力低下の削減を目指す国家プログラムが成長の機会を創出しています。眼科における非侵襲的治療法やデジタルヘルスツールの導入拡大も、カナダが北米の眼痛市場において果たす役割の拡大に貢献しています。
欧州眼痛市場に関する洞察
欧州の眼痛市場は、緑内障、ぶどう膜炎、ドライアイ症候群といった慢性および加齢に伴う眼疾患の増加を背景に、2025年には大きな市場シェアを占めました。この地域は、ユニバーサルヘルスケアへのアクセス、患者の高い認知度、処方薬および市販薬の点眼薬の普及といった恩恵を受けています。好ましい規制の枠組み、活発な臨床研究、そして大手眼科企業の存在が、引き続き地域全体の市場成長を支えています。
ドイツの眼痛市場に関する洞察
ドイツの眼痛市場は、先進的な医療インフラ、強力な製薬産業、そして高齢化人口の増加に支えられ、2025年には欧州で最大の収益シェアを占めました。早期診断と専門的な眼科医療サービスを重視していることから、眼痛治療に対する需要は堅調に推移しています。保険償還制度の整備と革新的な治療法の積極的な導入により、ドイツは欧州の眼痛市場における主要な貢献国としての地位を確立しています。
英国の眼痛市場に関する洞察
英国の眼痛市場は、眼の健康に対する意識の高まり、デジタル眼精疲労の増加、そして予防眼科ケアに重点を置いた政府主導の取り組みに支えられ、着実に成長しています。若年層におけるスクリーン関連の視力障害や片頭痛関連の眼痛の増加は、OTC製品や健康志向の眼科ソリューションの普及を促進しています。NHS（国民保健サービス）による眼科サービスへの支援拡大と小売薬局チェーンの存在は、市場へのアクセス性を高めています。
アジア太平洋地域の眼痛市場に関する洞察
アジア太平洋地域の眼痛治療市場は、2025年に世界の眼痛治療市場において最大のシェアを獲得し、総売上高の18.78%を占め、年平均成長率（CAGR）7.2%と最も高い成長が予測されています。この成長は、この地域の広大な農業基盤、海藻養殖活動の拡大、そして持続可能な農業慣行の導入の増加によって牽引されています。政府の補助金、環境意識の高まり、そしてオーガニック食品の需要増加により、地域全体で海藻肥料などのバイオベースの投入物への移行が加速しています。
中国の眼痛市場に関する洞察
中国の眼痛治療市場は、広大な海岸線、強力な海藻養殖能力、そして堅牢な加工インフラを背景に、2025年にはアジア太平洋地域市場をリードする規模となりました。中国政府による持続可能な農業の推進と、無農薬農産物に対する国内の高い需要が、海藻肥料の普及を後押ししています。海洋バイオテクノロジーへの戦略的投資と大規模メーカーの存在は、地域市場における中国のリーダーシップをさらに強化しています。
インドの眼痛市場に関する洞察
インドの眼痛治療市場は、有機農業への意識の高まり、PM-PRANAMやParamparagat Krishi Vikas Yojanaといった政府支援プログラム、そして土壌の健全性回復への関心の高まりを背景に、大幅な成長を遂げています。同国の農業労働力の多さと海藻肥料の低価格が、沿岸部および内陸部における穀物、野菜、豆類の栽培において、特に普及を促進しています。
眼痛の市場シェア
眼痛治療業界は、主に、次のような老舗企業によって牽引されています。
- アルコン社（スイス）
- アレルゲン（アイルランド）
- ボシュロム（米国）
- ノバルティスAG
- ケベニュー（米国）
- ファイザー社（米国）
- メルク・シャープ・アンド・ドーム社（メルク（米国）の子会社）
- オキュラー・セラピューティクス（米国）
- サン・ファーマシューティカル（インド）
- アイポイント・ファーマシューティカルズ（米国）
- フェラ・ファーマシューティカルズ（米国）
- IACTA製薬（米国）
- セラライフ®社（米国）
- オプティカルマ・インディアSMCプライベートリミテッド（インド）
- ウェロナファーマ（インド）
- オスカーレメディーズ株式会社（インド）
- オプデナスライフサイエンス（インド）
- Choroid Laboratories Pvt. Ltd.（インド）
- シレンティス（スペイン）
- ターシエ・ファーマ社（イスラエル）
- ビルマ（米国）
- オキョーファーマリミテッド（英国）
- アルデリア・セラピューティクス（米国）
- Novaliq GMBH（ドイツ）
- フォルモサファーマ製薬株式会社（台湾）
- iVIEW Therapeutics, Inc.（米国）
世界の眼痛市場の最新動向
- 2020年10月、Nevakar Inc.とZhaoke Ophthalmologyは、小児近視治療のための新規点眼薬NVK002の中華圏、韓国、および東南アジアにおける開発・商業化に関する独占ライセンス契約を締結しました。この契約には、最大1億200万米ドルのマイルストーンペイメントと段階的なロイヤリティが含まれており、Zhaokeは後期開発段階にあるこの革新的な治療法によって、この地域の近視治療をリードする立場にあります。
- 2021年1月、Nevakar Inc.とLaboratoires Théaは、欧州および北アフリカの一部地域におけるNVK002の商業化に関する独占ライセンス契約を締結しました。小児の近視進行抑制を目的とした治験用点眼薬NVK002は、現在第III相臨床試験中です。Nevakarは、契約締結地域における将来の売上に応じて段階的なロイヤルティに加え、最大1億3,500万ドルのマイルストーンペイメントを受け取る可能性があります。
- 2025年7月、ボシュロムは、防腐剤不使用の充血緩和点眼薬「ルミファイ」の第3相臨床試験データの公表を発表しました。この開発は、市販のアイケアにおけるイノベーションへの当社のコミットメントを裏付けるものです。防腐剤不使用のこの処方は、良好な安全性プロファイルを有し、迅速かつ持続的な充血軽減効果を示しました。この進歩により、ボシュロムは眼の快適性を高める製品ラインナップを拡大し、防腐剤不使用分野におけるブランドとしての確固たる地位を確立します。
- 2025年7月、アルデイラ・セラピューティクス社は、ドライアイ治療薬レプロキサラップの新薬承認申請（NDA）を再提出し、米国食品医薬品局（FDA）の審査に受理されたと発表しました。この再提出は、FDAが要求していた眼不快感の軽減という主要評価項目を達成した単一の臨床試験に基づいています。
- 2025年5月、ボシュロムは、人気のルミファイ製品ラインを拡充し、防腐剤不使用の充血緩和目薬「ルミファイ プレザベーションフリー レッドネス リリーバー アイドロップス」の米国での発売を発表しました。この新処方は防腐剤を使用せずに目の充血を緩和し、過敏症の患者様のニーズにも対応します。この発売は、ボシュロムの眼の健康におけるイノベーションへのコミットメントを強化するものであり、消費者の快適性と長期的な眼表面保護を目的とした市販のアイケア製品のポートフォリオを拡充するものです。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 GLOBAL OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.4 PATENT ANALYSIS-
4.5 SUPPLY CHAIN
4.6 VALUE CHAIN
5 TARIFF IMPACT ANALYSIS – GLOBAL OCULAR PAIN MARKET
5.1 IMPACT ON RAW MATERIAL AND API IMPORTS
5.2 FINISHED PRODUCT TARIFFS AND MARKET ACCESS
5.3 MEDICAL DEVICE COMPONENT TARIFFS
5.4 TRADE AGREEMENTS AND HARMONIZATION BENEFITS
5.5 STRATEGIC SHIFTS AND LOCALIZATION
6 GLOBAL OCULAR PAIN MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
7.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
7.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
7.1.4 GROWING CASES OF OCULAR MIGRAINE
7.2 RESTRAINTS
7.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
7.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS AND TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT RULES & REGULATIONS
7.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
8 GLOBAL OCULAR PAIN MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 OCULAR PAIN WITH EYE DISEASES
8.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
9 GLOBAL OCULAR PAIN MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.3 TREATMENT
10 GLOBAL OCULAR PAIN MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 GLAUCOMA
10.3 BLEPHARITIS
10.4 CONJUNCTIVITIS
10.5 CORNEAL ABRASION
10.6 STY
10.7 IRITIS
10.8 SINUSITIS
10.9 MIGRAINES
10.1 OTHERS
11 GLOBAL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 TOPICAL
11.3 INTRAOCULAR
11.4 PERIOCULAR
11.5 ORAL
11.6 OTHERS
12 GLOBAL OCULAR PAIN MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULT
12.3 GERIATRIC
13 GLOBAL OCULAR PAIN MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 GLOBAL OCULAR PAIN MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 HOME HEALTHCARE
14.5 OCULAR PAIN CENTERS
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 GLOBAL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
15.6 OTHERS
16 GLOBAL OCULAR PAIN MARKET, BY REGION
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 ITALY
16.3.3 FRANCE
16.3.4 U.K.
16.3.5 SPAIN
16.3.6 NETHERLANDS
16.3.7 RUSSIA
16.3.8 SWITZERLAND
16.3.9 TURKEY
16.3.10 AUSTRIA
16.3.11 NORWAY
16.3.12 HUNGARY
16.3.13 LITHUANIA
16.3.14 IRELAND
16.3.15 POLAND
16.3.16 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 JAPAN
16.4.2 CHINA
16.4.3 INDIA
16.4.4 SOUTH KOREA
16.4.5 AUSTRALIA
16.4.6 SINGAPORE
16.4.7 THAILAND
16.4.8 MALAYSIA
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 VIETNAM
16.4.12 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 PERU
16.5.4 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 SAUDI ARABIA
16.6.3 U.A.E.
16.6.4 EGYPT
16.6.5 KUWAIT
16.6.6 ISRAEL
16.6.7 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL OCULAR PAIN MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 ALCON INC
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 ALLERGAN (AN ABBVIE COMPANY)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 BAUSCH + LOMB
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 KENVUE
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 PFIZER INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ALDEYRA THERAPEUTICS, INC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT/NEWS
19.7 CHOROID LABORATORIES
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 EYEPOINT PHARMACEUTICALS, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 FERA PHARMACEUTICALS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 FORMOSAPHARMA PHARMACEUTICAL INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT NEWS
19.11 IACTA PHARMACEUTICALS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 IVIEW THERAPEUTICS, INC..
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 MERCK & CO., INC., A SUBSIDIARY OF MERCK
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 NOVALIQ GMBH
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 OCULAR THERAPEUTIX, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS/NEWS
19.16 OKYO PHARMA, LIMITED
19.16.1 COMPANY SNAPSHOT
19.16.2 1.1.4 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS/NEWS
19.17 OPDENAS LIFESCIENCES.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 OPTICARMA INDIA SMC PRIVATE LIMITED
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS/NEWS
19.19 OSCAR REMEDIES PVT. LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS/NEWS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 SYLENTIS
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENT
19.22 TARSIER PHARMA LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENT
19.23 THERALIFE, INC.
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENT
19.24 VYLUMA
19.24.1 COMPANY SNAPSHOT
19.24.2 PIPELINE PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 WELLONA PHARMA
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS/NEWS
20 QUESTIONNAIRE
21 RELATED REPORTS
表のリスト
TABLE 1 GLOBAL OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 GLOBAL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 GLOBAL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY TYPE OF DISEASE, 2018-2032 (USD THOUSAND)
TABLE 4 GLOBAL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 GLOBAL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 GLOBAL OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 GLOBAL DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 GLOBAL DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL SENSORY TESTING IN OCULAR PAIN IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL IMAGING TEST IN OCULAR PAIN IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL STY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL IRITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL ORAL IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL ADULT IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 GLOBAL GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 GLOBAL OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 GLOBAL PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 GLOBAL OVER THE COUNTER (OTC) IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 GLOBAL OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 44 GLOBAL HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 GLOBAL SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 GLOBAL HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 GLOBAL OCULAR PAIN CENTERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 GLOBAL AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 49 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 GLOBAL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 51 GLOBAL DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 52 GLOBAL HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 GLOBAL RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 54 GLOBAL ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 56 GLOBAL OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 75 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 U.S. OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 U.S. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 U.S. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 U.S. OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 U.S. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 U.S. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 U.S. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 U.S. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 U.S. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 U.S. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 U.S. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 97 U.S. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 CANADA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 CANADA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 CANADA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 CANADA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 CANADA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 CANADA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 CANADA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 CANADA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 CANADA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 CANADA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 CANADA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 CANADA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 CANADA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 115 CANADA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 116 CANADA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 117 CANADA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 118 CANADA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 119 CANADA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 MEXICO OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 MEXICO OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 MEXICO OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 MEXICO OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 MEXICO DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 MEXICO SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 MEXICO IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 MEXICO TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 MEXICO LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 MEXICO TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 MEXICO STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 MEXICO OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 137 MEXICO OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 138 MEXICO TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 139 MEXICO INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 140 MEXICO PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 141 MEXICO ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 142 MEXICO OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 MEXICO OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 MEXICO OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 145 MEXICO OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 146 EUROPE OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 147 EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 EUROPE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 EUROPE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 EUROPE OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 EUROPE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 EUROPE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 EUROPE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 EUROPE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 EUROPE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 EUROPE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 EUROPE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 EUROPE OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 160 EUROPE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 161 EUROPE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 162 EUROPE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 163 EUROPE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 164 EUROPE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 165 EUROPE OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 EUROPE OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 EUROPE OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 168 EUROPE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 169 GERMANY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 GERMANY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 GERMANY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 GERMANY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 GERMANY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 GERMANY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 GERMANY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 GERMANY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 GERMANY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 GERMANY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 GERMANY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 GERMANY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 182 GERMANY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 183 GERMANY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 184 GERMANY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 185 GERMANY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 186 GERMANY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 187 GERMANY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 GERMANY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 GERMANY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 190 GERMANY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 191 ITALY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 ITALY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 ITALY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 ITALY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 ITALY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 ITALY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 ITALY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 ITALY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 ITALY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 ITALY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 ITALY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 ITALY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 ITALY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 204 ITALY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 205 ITALY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 206 ITALY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 207 ITALY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 208 ITALY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 209 ITALY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 ITALY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 ITALY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 212 ITALY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 213 FRANCE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 FRANCE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 FRANCE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 FRANCE OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 FRANCE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 FRANCE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 FRANCE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 FRANCE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 FRANCE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 FRANCE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 FRANCE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 FRANCE OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 226 FRANCE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 227 FRANCE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 228 FRANCE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 229 FRANCE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 230 FRANCE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 231 FRANCE OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 FRANCE OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 FRANCE OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 234 FRANCE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 235 U.K. OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 U.K. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 U.K. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 U.K. OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 U.K. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 U.K. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 U.K. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 U.K. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 U.K. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 U.K. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 U.K. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 U.K. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 U.K. OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 248 U.K. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 249 U.K. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 250 U.K. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 251 U.K. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 252 U.K. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 253 U.K. OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 U.K. OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 U.K. OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 256 U.K. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 257 SPAIN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 SPAIN OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 SPAIN OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 SPAIN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 SPAIN DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 SPAIN SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 SPAIN IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 SPAIN TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 SPAIN LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 SPAIN TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 SPAIN STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 SPAIN OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 270 SPAIN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 271 SPAIN TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 272 SPAIN INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 273 SPAIN PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 274 SPAIN ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 275 SPAIN OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 SPAIN OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 SPAIN OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 278 SPAIN OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 279 NETHERLANDS OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 NETHERLANDS OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 NETHERLANDS OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 NETHERLANDS OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 NETHERLANDS DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 NETHERLANDS SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 NETHERLANDS IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 NETHERLANDS TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 NETHERLANDS LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 NETHERLANDS TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 NETHERLANDS STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 NETHERLANDS OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 NETHERLANDS OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 293 NETHERLANDS TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 294 NETHERLANDS INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 295 NETHERLANDS PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 296 NETHERLANDS ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 297 NETHERLANDS OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 NETHERLANDS OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 NETHERLANDS OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 300 NETHERLANDS OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 301 RUSSIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 RUSSIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 RUSSIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 RUSSIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 RUSSIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 RUSSIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 RUSSIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 RUSSIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 RUSSIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 RUSSIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 RUSSIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 RUSSIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 314 RUSSIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 315 RUSSIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 316 RUSSIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 317 RUSSIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 318 RUSSIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 319 RUSSIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 RUSSIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 RUSSIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 322 RUSSIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 323 SWITZERLAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 SWITZERLAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 SWITZERLAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 SWITZERLAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 SWITZERLAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 SWITZERLAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 SWITZERLAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 SWITZERLAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 SWITZERLAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 SWITZERLAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 SWITZERLAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 SWITZERLAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 336 SWITZERLAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 337 SWITZERLAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 338 SWITZERLAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 339 SWITZERLAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 340 SWITZERLAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 341 SWITZERLAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 SWITZERLAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 SWITZERLAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 344 SWITZERLAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 345 TURKEY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 TURKEY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 TURKEY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 TURKEY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 TURKEY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 TURKEY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 TURKEY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 TURKEY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 TURKEY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 TURKEY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 TURKEY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 TURKEY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 358 TURKEY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 359 TURKEY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 360 TURKEY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 361 TURKEY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 362 TURKEY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 363 TURKEY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 TURKEY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 TURKEY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 366 TURKEY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 367 AUSTRIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 AUSTRIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 AUSTRIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 AUSTRIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 371 AUSTRIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 AUSTRIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 AUSTRIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 AUSTRIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 AUSTRIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 AUSTRIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 378 AUSTRIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 AUSTRIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 380 AUSTRIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 381 AUSTRIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 382 AUSTRIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 383 AUSTRIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 384 AUSTRIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 385 AUSTRIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 AUSTRIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 AUSTRIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 388 AUSTRIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 389 NORWAY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 NORWAY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 NORWAY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 NORWAY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 NORWAY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 NORWAY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 NORWAY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 NORWAY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 NORWAY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 NORWAY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 NORWAY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 NORWAY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 402 NORWAY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 403 NORWAY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 404 NORWAY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 405 NORWAY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 406 NORWAY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 407 NORWAY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 NORWAY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 NORWAY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 410 NORWAY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 411 HUNGARY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 HUNGARY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 HUNGARY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 HUNGARY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 HUNGARY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 HUNGARY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 HUNGARY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 HUNGARY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 HUNGARY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 HUNGARY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 HUNGARY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 HUNGARY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 424 HUNGARY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 425 HUNGARY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 426 HUNGARY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 427 HUNGARY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 428 HUNGARY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 429 HUNGARY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 HUNGARY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 HUNGARY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 432 HUNGARY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 433 LITHUANIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 LITHUANIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 LITHUANIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 LITHUANIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 LITHUANIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 LITHUANIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 439 LITHUANIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 LITHUANIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 LITHUANIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 LITHUANIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 444 LITHUANIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 445 LITHUANIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 446 LITHUANIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 447 LITHUANIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 448 LITHUANIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 449 LITHUANIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 450 LITHUANIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 451 LITHUANIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 LITHUANIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 LITHUANIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 454 LITHUANIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 455 IRELAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 IRELAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 IRELAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 IRELAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 IRELAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 IRELAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 IRELAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 IRELAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 IRELAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 IRELAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 IRELAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 IRELAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 468 IRELAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 469 IRELAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 470 IRELAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 471 IRELAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 472 IRELAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 473 IRELAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 IRELAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 IRELAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 476 IRELAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 477 POLAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 POLAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 POLAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 POLAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 POLAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 POLAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 POLAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 POLAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 POLAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 POLAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 POLAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 POLAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 POLAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 490 POLAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 491 POLAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 492 POLAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 493 POLAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 494 POLAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 495 POLAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 POLAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 POLAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 498 POLAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 499 REST OF EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 ASIA-PACIFIC OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 501 ASIA-PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 ASIA-PACIFIC OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 ASIA-PACIFIC OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 ASIA-PACIFIC OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 ASIA-PACIFIC DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 ASIA-PACIFIC SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 ASIA-PACIFIC IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 ASIA-PACIFIC TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 ASIA-PACIFIC LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 ASIA-PACIFIC TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 ASIA-PACIFIC STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 513 ASIA-PACIFIC OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 514 ASIA-PACIFIC OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 515 ASIA-PACIFIC TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 516 ASIA-PACIFIC INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 517 ASIA-PACIFIC PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 518 ASIA-PACIFIC ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 519 ASIA-PACIFIC OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 ASIA-PACIFIC OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 ASIA-PACIFIC OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 522 ASIA-PACIFIC OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 523 JAPAN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 JAPAN OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 JAPAN OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 JAPAN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 JAPAN DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 JAPAN SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 JAPAN IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 JAPAN TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 JAPAN LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 JAPAN TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 533 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 JAPAN STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 JAPAN OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 536 JAPAN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 537 JAPAN TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 538 JAPAN INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 539 JAPAN PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 540 JAPAN ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 541 JAPAN OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 JAPAN OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 JAPAN OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 544 JAPAN OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 545 CHINA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 CHINA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 547 CHINA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 CHINA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 CHINA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 CHINA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 CHINA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 CHINA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 CHINA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 CHINA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 CHINA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 CHINA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 CHINA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 558 CHINA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 559 CHINA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 560 CHINA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 561 CHINA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 562 CHINA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 563 CHINA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 564 CHINA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 CHINA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 566 CHINA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 567 INDIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 INDIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 INDIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 INDIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 INDIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 INDIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 INDIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 INDIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 575 INDIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 INDIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 INDIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 INDIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 INDIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 580 INDIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 581 INDIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 582 INDIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 583 INDIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 584 INDIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 585 INDIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 INDIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 INDIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 588 INDIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 589 SOUTH KOREA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 SOUTH KOREA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 591 SOUTH KOREA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 592 SOUTH KOREA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 SOUTH KOREA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 SOUTH KOREA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 SOUTH KOREA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 SOUTH KOREA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 SOUTH KOREA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 SOUTH KOREA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 SOUTH KOREA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 SOUTH KOREA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 602 SOUTH KOREA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 603 SOUTH KOREA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 604 SOUTH KOREA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 605 SOUTH KOREA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 606 SOUTH KOREA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 607 SOUTH KOREA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 SOUTH KOREA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 SOUTH KOREA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 610 SOUTH KOREA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 611 AUSTRALIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 AUSTRALIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 AUSTRALIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 AUSTRALIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 AUSTRALIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 AUSTRALIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 AUSTRALIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 AUSTRALIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 AUSTRALIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 AUSTRALIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 AUSTRALIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 AUSTRALIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 624 AUSTRALIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 625 AUSTRALIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 626 AUSTRALIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 627 AUSTRALIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 628 AUSTRALIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 629 AUSTRALIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 AUSTRALIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 AUSTRALIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 632 AUSTRALIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 633 SINGAPORE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 SINGAPORE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 SINGAPORE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 SINGAPORE OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 SINGAPORE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 SINGAPORE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 SINGAPORE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 SINGAPORE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 641 SINGAPORE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 642 SINGAPORE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 SINGAPORE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 SINGAPORE OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 646 SINGAPORE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 647 SINGAPORE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 648 SINGAPORE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 649 SINGAPORE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 650 SINGAPORE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 651 SINGAPORE OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 652 SINGAPORE OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 653 SINGAPORE OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 654 SINGAPORE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 655 THAILAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 THAILAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 THAILAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 THAILAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 THAILAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 THAILAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 THAILAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 THAILAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 THAILAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 THAILAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 THAILAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 THAILAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 668 THAILAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 669 THAILAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 670 THAILAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 671 THAILAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 672 THAILAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 673 THAILAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 THAILAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 THAILAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 676 THAILAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 677 MALAYSIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 MALAYSIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 MALAYSIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 680 MALAYSIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 681 MALAYSIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 MALAYSIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 683 MALAYSIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 684 MALAYSIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 MALAYSIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 MALAYSIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 MALAYSIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 689 MALAYSIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 690 MALAYSIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 691 MALAYSIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 692 MALAYSIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 693 MALAYSIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 694 MALAYSIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 695 MALAYSIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 MALAYSIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 MALAYSIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 698 MALAYSIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 699 INDONESIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 700 INDONESIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 INDONESIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 INDONESIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 703 INDONESIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 INDONESIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 INDONESIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 INDONESIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 INDONESIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 INDONESIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 INDONESIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 711 INDONESIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 712 INDONESIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 713 INDONESIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 714 INDONESIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 715 INDONESIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 716 INDONESIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 717 INDONESIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 718 INDONESIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 INDONESIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 720 INDONESIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 721 PHILIPPINES OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 PHILIPPINES OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 PHILIPPINES OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 724 PHILIPPINES OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 PHILIPPINES DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 PHILIPPINES SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 PHILIPPINES IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 PHILIPPINES TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 PHILIPPINES LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 PHILIPPINES TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 PHILIPPINES STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 733 PHILIPPINES OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 734 PHILIPPINES OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 735 PHILIPPINES TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 736 PHILIPPINES INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 737 PHILIPPINES PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 738 PHILIPPINES ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 739 PHILIPPINES OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 PHILIPPINES OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 741 PHILIPPINES OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 742 PHILIPPINES OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 743 VIETNAM OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 VIETNAM OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 VIETNAM OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 VIETNAM OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 747 VIETNAM DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 748 VIETNAM SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 749 VIETNAM IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 VIETNAM TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 VIETNAM LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 VIETNAM TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 VIETNAM STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 VIETNAM OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 756 VIETNAM OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 757 VIETNAM TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 758 VIETNAM INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 759 VIETNAM PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 760 VIETNAM ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 761 VIETNAM OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 VIETNAM OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 VIETNAM OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 764 VIETNAM OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 765 REST OF ASIA-PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 SOUTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 767 SOUTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 768 SOUTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 SOUTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 SOUTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 SOUTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 SOUTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 SOUTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 774 SOUTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 SOUTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 776 SOUTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 777 SOUTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 778 SOUTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 779 SOUTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 780 SOUTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 781 SOUTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 782 SOUTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 783 SOUTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 784 SOUTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 785 SOUTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 786 SOUTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 SOUTH AMERICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 788 SOUTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 789 BRAZIL OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 790 BRAZIL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 791 BRAZIL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 BRAZIL OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 BRAZIL DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 BRAZIL SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 795 BRAZIL IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 796 BRAZIL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 797 BRAZIL LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 BRAZIL TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 BRAZIL NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 800 BRAZIL STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 801 BRAZIL OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 802 BRAZIL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 803 BRAZIL TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 804 BRAZIL INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 805 BRAZIL PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 806 BRAZIL ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 807 BRAZIL OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 808 BRAZIL OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 809 BRAZIL OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 810 BRAZIL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 811 ARGENTINA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 812 ARGENTINA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 813 ARGENTINA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 814 ARGENTINA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 815 ARGENTINA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 816 ARGENTINA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 817 ARGENTINA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 ARGENTINA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 ARGENTINA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 820 ARGENTINA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 821 ARGENTINA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 822 ARGENTINA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 823 ARGENTINA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 824 ARGENTINA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 825 ARGENTINA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 826 ARGENTINA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 827 ARGENTINA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 828 ARGENTINA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 829 ARGENTINA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 830 ARGENTINA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 ARGENTINA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 832 ARGENTINA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 833 PERU OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 834 PERU OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 835 PERU OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 836 PERU OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 837 PERU DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 838 PERU SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 839 PERU IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 840 PERU TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 841 PERU LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 842 PERU TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 843 PERU NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 844 PERU STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 845 PERU OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 846 PERU OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 847 PERU TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 848 PERU INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 849 PERU PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 850 PERU ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 851 PERU OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 852 PERU OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 853 PERU OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 854 PERU OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 855 REST OF SOUTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 856 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 857 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 858 MIDDLE EAST AND AFRICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 859 MIDDLE EAST AND AFRICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 860 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 861 MIDDLE EAST AND AFRICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 862 MIDDLE EAST AND AFRICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 863 MIDDLE EAST AND AFRICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 864 MIDDLE EAST AND AFRICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 865 MIDDLE EAST AND AFRICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 866 MIDDLE EAST AND AFRICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 867 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 868 MIDDLE EAST AND AFRICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 869 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 870 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 871 MIDDLE EAST AND AFRICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 872 MIDDLE EAST AND AFRICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 873 MIDDLE EAST AND AFRICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 874 MIDDLE EAST AND AFRICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 875 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 876 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 878 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 879 SOUTH AFRICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 880 SOUTH AFRICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 881 SOUTH AFRICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 882 SOUTH AFRICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 SOUTH AFRICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 884 SOUTH AFRICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 885 SOUTH AFRICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 886 SOUTH AFRICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 887 SOUTH AFRICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 888 SOUTH AFRICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 889 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 890 SOUTH AFRICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 891 SOUTH AFRICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 892 SOUTH AFRICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 893 SOUTH AFRICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 894 SOUTH AFRICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 895 SOUTH AFRICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 896 SOUTH AFRICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 897 SOUTH AFRICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 898 SOUTH AFRICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 899 SOUTH AFRICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 900 SOUTH AFRICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 901 SAUDI ARABIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 902 SAUDI ARABIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 903 SAUDI ARABIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 904 SAUDI ARABIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 905 SAUDI ARABIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 906 SAUDI ARABIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 907 SAUDI ARABIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 908 SAUDI ARABIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 SAUDI ARABIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 910 SAUDI ARABIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 911 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 912 SAUDI ARABIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 913 SAUDI ARABIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 914 SAUDI ARABIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 915 SAUDI ARABIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 916 SAUDI ARABIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 917 SAUDI ARABIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 918 SAUDI ARABIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 919 SAUDI ARABIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 920 SAUDI ARABIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 921 SAUDI ARABIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 922 SAUDI ARABIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 923 U.A.E. OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 924 U.A.E. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 925 U.A.E. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 926 U.A.E. OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 927 U.A.E. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 928 U.A.E. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 929 U.A.E. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 930 U.A.E. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 931 U.A.E. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 932 U.A.E. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 933 U.A.E. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 934 U.A.E. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 935 U.A.E. OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 936 U.A.E. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 937 U.A.E. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 938 U.A.E. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 939 U.A.E. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 940 U.A.E. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 941 U.A.E. OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 942 U.A.E. OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 943 U.A.E. OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 944 U.A.E. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 945 EGYPT OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 946 EGYPT OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 947 EGYPT OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 948 EGYPT OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 949 EGYPT DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 950 EGYPT SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 951 EGYPT IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 952 EGYPT TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 953 EGYPT LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 954 EGYPT TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 955 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 956 EGYPT STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 957 EGYPT OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 958 EGYPT OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 959 EGYPT TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 960 EGYPT INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 961 EGYPT PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 962 EGYPT ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 963 EGYPT OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 964 EGYPT OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 965 EGYPT OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 966 EGYPT OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 967 KUWAIT OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 968 KUWAIT OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 969 KUWAIT OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 970 KUWAIT OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 971 KUWAIT DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 972 KUWAIT SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 973 KUWAIT IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 974 KUWAIT TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 975 KUWAIT LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 976 KUWAIT TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 977 KUWAIT NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 978 KUWAIT STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 979 KUWAIT OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 980 KUWAIT OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 981 KUWAIT TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 982 KUWAIT INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 983 KUWAIT PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 984 KUWAIT ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 985 KUWAIT OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 986 KUWAIT OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 987 KUWAIT OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 988 KUWAIT OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 989 ISRAEL OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 990 ISRAEL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 991 ISRAEL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 992 ISRAEL OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 993 ISRAEL DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 994 ISRAEL SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 995 ISRAEL IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 996 ISRAEL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 997 ISRAEL LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 998 ISRAEL TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 999 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1000 ISRAEL STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1001 ISRAEL OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 1002 ISRAEL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1003 ISRAEL TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1004 ISRAEL INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1005 ISRAEL PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 1006 ISRAEL ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1007 ISRAEL OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1008 ISRAEL OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 1009 ISRAEL OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1010 ISRAEL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1011 REST OF MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
図表一覧
FIGURE 1 GLOBAL OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 GLOBAL OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL OCULAR PAIN MARKET: GLOBAL VS REGIONAL ANALYSIS
FIGURE 5 GLOBAL OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 GLOBAL OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 GLOBAL OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 GLOBAL OCULAR PAIN MARKET: EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OCULAR PAIN MARKET, AND IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE GLOBAL OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OCULAR PAIN MARKET IN 2025 AND 2032
FIGURE 16 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR OCULAR PAIN MANUFACTURERS IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 17 COUNTRY V/S NUMBER OF PATENTS
FIGURE 18 KEY APPLICANTS V/S NUMBER OF PATENTS.
FIGURE 19 INTERNATIONAL PATENT CLASSIFICATION V/S NUMBER OF PATENTS
FIGURE 20 NUMBER OF PATENT PUBLICATIONS PER YEAR.
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL OCULAR PAIN MARKET
FIGURE 22 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, 2024
FIGURE 23 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 24 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2025- 2032)
FIGURE 25 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 26 GLOBAL OCULAR PAIN MARKET: BY TYPE, 2024
FIGURE 27 GLOBAL OCULAR PAIN MARKET: BY TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 28 GLOBAL OCULAR PAIN MARKET: BY TYPE, CAGR (2025- 2032)
FIGURE 29 GLOBAL OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, 2024
FIGURE 31 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 32 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 33 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 35 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 36 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 37 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, 2024
FIGURE 39 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 40 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2025- 2032)
FIGURE 41 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 42 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, 2024
FIGURE 43 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 44 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2025- 2032)
FIGURE 45 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 46 GLOBAL OCULAR PAIN MARKET: BY END USER, 2024
FIGURE 47 GLOBAL OCULAR PAIN MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 48 GLOBAL OCULAR PAIN MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 49 GLOBAL OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 50 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 51 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 52 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 53 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 54 GLOBAL OCULAR PAIN MARKET: SNAPSHOT (2024)
FIGURE 55 GLOBAL OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
FIGURE 56 NORTH AMERICA OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
FIGURE 57 EUROPE OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
FIGURE 58 ASIA-PACIFIC OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
